Recommendations for permanent dose modification for your patients who experience hematologic toxicities

Severe neutropenia and thrombocytopenia
ANC=absolute neutrophil count.
Non-small cell lung cancer dose adjustments for hematologic toxicity
Non-small cell lung cancer dose adjustments for hematologic toxicity
Non-small cell lung cancer dose adjustments for hematologic toxicity
Non-small cell lung cancer dose adjustments for hematologic toxicity
Non-small cell lung cancer dose adjustments for hematologic toxicity

Illustrative purposes only.

  • In the phase 3 ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grade 1-4 neutropenia; 47% experienced Grade 3-4 neutropenia
  • In the phase 3 ABRAXANE NSCLC clinical trial, 68% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grade 1-4 thrombocytopenia; 18% experienced Grade 3-4 thrombocytopenia

Recommendations for permanent dose modification for your patients whoexperience hematologic toxicities

Initial Treatment

  • Do not administer ABRAXANE on Day 1 of a cycle until ANC is ≥1500 cells/mm3 and platelet count is ≥100,000 cells/mm3

Neutropenia

  • Nadir ANC <500 cells/mm3 with neutropenic fever >38° C, OR
  • Delay of next cycle by more than 7 days for nadir ANC <1500/mm3, OR
  • Nadir ANC <500 cells/mm3 for >1 week

Make a selection

  • First Occurrence
  • Second Occurrence
  • Third Occurrence
  • In the phase 3 ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grade 1-4 neutropenia; 47% experienced Grade 3-4 neutropenia
  • In the phase 3 ABRAXANE NSCLC clinical trial, 68% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grade 1-4 thrombocytopenia; 18% experienced Grade 3-4 thrombocytopenia
first occurrence bottles
second occurrence bottles
third occurrence bottles
first occurrence bottles
second occurrence bottles

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.